GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » Operating Margin %

ALLO (Allogene Therapeutics) Operating Margin % : 0.00% (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Allogene Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Allogene Therapeutics's Operating Income for the three months ended in Mar. 2025 was $-65.19 Mil. Allogene Therapeutics's Revenue for the three months ended in Mar. 2025 was $0.00 Mil. Therefore, Allogene Therapeutics's Operating Margin % for the quarter that ended in Mar. 2025 was 0.00%.

The historical rank and industry rank for Allogene Therapeutics's Operating Margin % or its related term are showing as below:


ALLO's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -115.49
* Ranked among companies with meaningful Operating Margin % only.

Allogene Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Allogene Therapeutics's Operating Income for the three months ended in Mar. 2025 was $-65.19 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was $-253.17 Mil.


Allogene Therapeutics Operating Margin % Historical Data

The historical data trend for Allogene Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allogene Therapeutics Operating Margin % Chart

Allogene Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Margin %
Get a 7-Day Free Trial - -157.94 -215,087.18 -331,044.21 -1,170,372.73

Allogene Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -315,927.27 - - - -

Competitive Comparison of Allogene Therapeutics's Operating Margin %

For the Biotechnology subindustry, Allogene Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allogene Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Allogene Therapeutics's Operating Margin % falls into.


;
;

Allogene Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Allogene Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-257.482 / 0.022
=-1,170,372.73 %

Allogene Therapeutics's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=-65.191 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allogene Therapeutics  (NAS:ALLO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Allogene Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Allogene Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Allogene Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
210 East Grand Avenue, South San Francisco, CA, USA, 94080
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Executives
David D Chang director, officer: President and CEO C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Deborah M. Messemer director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Earl Martin Douglas officer: GENERAL COUNSEL BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067
Zachary Roberts officer: EVP of R&D C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Geoffrey M. Parker officer: CHIEF FINANCIAL OFFICER 15 RIORDAN PLACE, MENLO PARK CA 94025
Timothy L. Moore officer: Chief Technical Officer C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Franz B Humer director 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
Arie Belldegrun director, 10 percent owner UCLA SCHOOL OF MEDICINE, 10833 LE CONTE 66-118 CHS BOX 951738, LOS ANGELES CA 9095-1738
Yinlin Jack Chen officer: SVP, Finance 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lillian Smith officer: VP, Corporate Counsel 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Veer Bhavnagri officer: General Counsel C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Owen N. Witte director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rafael Amado officer: EVP of R&D and CMO 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Alison Moore officer: Chief Technical Officer C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080